What is the long-term trend for Ashland's unallocated and other — research and development expense?

Over 2 years (2023 to 2025), Ashland's unallocated and other — research and development expense has grown at a 0.0% compound annual growth rate (CAGR), from $2M to $2M.

Ashland (ASH) Unallocated And Other — Research And Development Expense

Screener

Other segment segments

Personal Care And Household

$6M0.0%

Specialty Additives

$4M+33.3%

Intermediates And Solvents

$0—

Similar metrics at other companies

HLIOUnallocated Expenses — Research And Development Expense

$0—

BEAMExternal Research And Development Expenses — Research And Development Expense

$30.08M-12.6%

IRONOther Research — Research And Development Expense

$2.17M+18.2%

SLDBInternal Research And Development Expense — Research And Development Expense

$9.06M+33.9%

IRONInternal Research And Development — Research And Development Expense

$11.31M+67.6%

RNTXFacilities And Other Expenses — Research And Development Expense

$25K+56.3%

Other financials

Income statement

See full

Revenue$497.0M+7.3%

Gross profit$170.0M+28.8%

Operating income$43.0M+106%

Net income$16.0M+102%

EPS (diluted)$0.35+102%

Balance sheet

See full

Cash & equivalents$440.0M+113%

Total debt$1.5B-0.6%

Total equity$1.9B-1.0%

Total assets$4.6B-0.9%

Cash flow

See full

Operating cash flow$120.0M+4.3%

CapEx$20.0M0.0%

Free cash flow$100.0M+5.3%

Valuation

See full

Market cap$3.32B+40.6%

Enterprise value$4.35B+19.7%

P/E165.9×—

P/S1.8×+0.5×

Profitability

See full

Gross margin31.5%+1.4pp

Operating margin4.1%—

Net margin1.1%+0.5pp

FCF margin13.6%+9.7pp

Returns & leverage

See full

Return on equity1.1%+0.5pp

Debt / equity0.8×0.0×

Current ratio3×+0.4×

Where this comes from

Reported directly by Ashland in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Ashland’s 10-Q, filed July 29, 2026.

Filed: Jul 29, 2026, 5:17 PM EDT
Fiscal quarter: Q3 FY2026
Calendar quarter: Q2 2026
Accession: 0001193125-26-324226

(In millions - unaudited)	Three months ended / June 30 / 2026	Three months ended / June 30 / 2025	Nine months ended / June 30 / 2026	Nine months ended / June 30 / 2025
Specialty Additives	4	3	10	8
Intermediates	—	—	1	—
Total operating segments	14	13	39	39
Unallocated and other	1	—	2	2
	$15	$13	$41	$41
Amortization expense
Life Sciences	$5	$5	$14	$13
Personal Care	8	8	25	26

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ashland's unallocated and other — research and development expense?: Ashland (ASH) reported unallocated and other — research and development expense of $1M in Q2 2026.
What is the long-term trend for Ashland's unallocated and other — research and development expense?: Over 2 years (2023 to 2025), Ashland's unallocated and other — research and development expense has grown at a 0.0% compound annual growth rate (CAGR), from $2M to $2M.
What does unallocated and other — research and development expense mean?: Captures research and development expenditures that are managed at the corporate level rather than allocated to specific business units. This reflects centralized innovation efforts or exploratory projects that do not yet have a dedicated segment home.